Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
Recruitment status was Recruiting
The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma|
- B2AR polymorphisms associated with albuterol responsiveness in acute asthma. [ Time Frame: ~ 1 hour following 3 doses of albuterol Q 20 min ] [ Designated as safety issue: No ]
- B2AR haplotypes [ Time Frame: ~ 1hr post 3 doses of albuterol ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
DNA for analysis of B2AR polymorphysims, DNA for genes for inflamation,steroid and leukotriene responsiveness.
|Study Start Date:||December 2009|
|Estimated Study Completion Date:||January 2012|
|Estimated Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Those who respond clinically to albuterol.
Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016444
|Contact: Robynn Cox, RNemail@example.com|
|Contact: Cynthia Newnan, RNfirstname.lastname@example.org|
|United States, Ohio|
|MetroHealth Medical Center||Recruiting|
|Cleveland, Ohio, United States, 44109|
|Contact: Robynn Cox, RN 216-778-3227 email@example.com|
|Contact: Cynthia Newman, RN 216-778-3237 firstname.lastname@example.org|
|Principal Investigator: E. R. Mc Fadden, Jr, MD,|